Litcius/Paper detail

Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial

Wendy Landier, Smita Bhatia, F. Lennie Wong, Jocelyn M. York, Jessica S. Flynn, Harrison Henneberg, Purnima Singh, Kandice Adams, Karen Wasilewski‐Masker, Brooke Cherven, Rama Jasty‐Rao, Marcia Leonard, James A. Connelly, Saro H. Armenian, Leslie L. Robison, Anna R. Giuliano, Melissa M. Hudson, James L. Klosky

2021The Lancet Child & Adolescent Health14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineImmunogenicityCancerPopulationHPV vaccinesClinical trialYoung adultCervical cancerGardasilInternal medicineVaccinationClinical endpointOncologyHPV infectionImmunologyAntibodyEnvironmental healthCervical Cancer and HPV ResearchHead and Neck Cancer StudiesLymphadenopathy Diagnosis and Analysis
Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial | Litcius